ArticleEuropean journal of nuclear medicine and molecular imaging2026
Tumour-absorbed dose and efficacy of peptide receptor radionuclide therapy with [
Article in European journal of nuclear medicine and molecular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimThe management of treatment-refractory meningioma in patients with previous surgical resection and radiation therapy remains challenging due to the lack of effective systemic treatment options. Therefore, novel therapeutic applications, such as peptide receptor radionuclide therapy (PRRT) targeting somatostatin receptors, may offer a promising therapeutic strategy. We aimed to assess the lesion-based tumour-absorbed dose and efficacy of PRRT with [ MATERIALS AND
methodsIn this study, 10 patients with therapy-refractory meningioma were retrospectively included. All patients received systemic [
resultsThe median cumulative activity administered per patient was 3804 MBq (IQR, 3140-4050 MBq), with a median of 3 cycles (range: 1-7). On lesion-based analysis following PRRT, response assessment was available in 19/21 (91.5%) lesions. Among these, tumour stabilisation according to RANO criteria was observed in 7/19 (36.8%) lesions, with a median cumulative tumour-absorbed dose of 52.7 Gy. Morphological tumour progression was noted in 12/19 (63.2%) lesions, with a median cumulative tumour-absorbed dose of 43.8 Gy. The difference in tumour-absorbed doses between morphologically stable and progressive lesions according to RANO criteria was not statistically significant (P = 0.82). Values for SUVmax and SUVmean from pretherapeutic [
conclusionOur preliminary results indicate no significant difference in tumour-absorbed doses between morphologically stable lesions and those with progressive disease, as defined by the RANO criteria. However, lesion-based analysis revealed a significant correlation between pretherapeutic [
Indexed as
Identifiers
42554825What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.